"Dibenzepin"

Dibenzepin and amitriptyline in depressive states: comparative double-blind trial. Dibenzepin and amitriptyline appeared to be equally efficacious in controlling target symptoms of depressive reactions. These results appear to be consistent with pharmacological profiles of the two drugs which are both tricylic compounds. Control of target symptoms occurred in an undulating and non-progressive manner in both groups. Aggravation of depressive symptomatology in the third week of treatment was noted in both groups and appeared to be clinically very important in the management of depressed patients. Dibenzepin caused relatively fewer side effects which appears to be an advantage over amitriptyline. Dibenzepin appeared to be a suitable alternative for amitriptyline intolerant patients

[Logical analysis of the respective influence of 3 experimental variables using a diagram by L. Carroll. Application of this method to a clinical trial of 2 forms of Noveril]. The analysis of the results gathered in a double-blind randomized cross-over clinical trial of dibenzepine was systematized in order to evidence the relation existing between the experimental variables and the effects

Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. A rapid, sensitive and specific method to quantify nevirapine in human plasma using dibenzepine as the internal standard (IS) was developed and validated. The method employed a liquid-liquid extraction. The analyte

or equivalent (greater than or equal to 150 mg/day or minimum dose of 2.5 mg/kg of body weight), phenelzine (greater than or equal to 60 mg/day), maprotiline (150-200 mg/day), fluvoxamine (greater than or equal to 150 mg/day), dibenzepine (greater than or equal to 480 mg/day), fluoxetine (20 mg/day), lofepramine (140-210 mg/day) and citalopram (40-60 mg/day)). All studies compared placebo addition in place

Drug induced VATER association: is dibenzepin a possible cause?

A double-blind comparative trial of dibenzepin and imipramine.

* Dibenzepin * Dimetacrine‡ * Dosulepin * Doxepin

* Dibenzepin * Dimetacrine‡ * Dosulepin * Doxepin

* Dibenzepin * Dimetacrine‡ * Dosulepin * Doxepin

1,550 66–198 ≥1,990 ≥1,610 Dibenzepin ND ND >10,000 >10,000 ≥1,500 ND ND ND >10,000 >10,000 >10,000 23 1,950 1,750 (by at least 10-fold over serotonin) include: * Desipramine (Norpramin, Pertofrane) * Dibenzepin‡ (Noveril, Victoril) * Lofepramine§ (Lomont, Gamanil) * Maprotiline (Ludiomil) – can be classed with the TCAs though more frequently classed with the TeCAs * Nortriptyline (Pamelor, Aventyl, Norpress) * Protriptyline (Vivactil)Whereas either fairly balanced reuptake inhibitors of serotonin and norepinephrine